Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023)
Perspective Therapeutics (CATX) posted Income from Non-Controlling Interests of $15000.0 for Q2 2023, down 68.75% sequentially from $48000.0 in Q4 2016.
Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023) Analysis & Trends
Perspective Therapeutics has reported Income from Non-Controlling Interests for 2 years, with the latest figure at $15000.0 in Q2 2023.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $15000.0 in Q2 2023, while the trailing twelve-month figure through Sep 2024 was $15000.0 (changed 0.0% YoY) and the FY2017 annual result came in at $48000.0, down 89.47% from the prior year.
- Income from Non-Controlling Interests slipped to $15000.0 in Q2 2023 per CATX's latest filing, from $48000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $15000.0 in Q2 2023 and troughed at $15000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -500,000.00 |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 13.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 2.32 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 900,000.00 |
| 10 | Perspective Therapeutics | 384.27 Mn | 384.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 15,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Jun 30, 2016 | 456,000.00 |